Literature DB >> 34983717

Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management.

Vesna Grivcheva-Panovska1, Timothy J Craig2, Hilary Longhurst3, Noémi Bara4, Irina Panovska5.   

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has greatly affected health-care provision across the globe. Management of chronic ailments has become challenging because of the strained health-care resources and social distancing measures that prevent on-site clinical visits and treatments. Hereditary angioedema (HAE) is a debilitating, chronic disease characterized by unpredictable swelling attacks in various parts of the body. Controlling HAE symptoms often requires long-term prophylactic medication use and regular medical care; however, limited scientific information has been published about HAE medical care during the COVID-19 pandemic. Objective: To gather patient and health-care professional (HCP) perspectives on the global impact that COVID-19 has had, and the future impact it will have on HAE medical care and to identify differences in perceptions across economic and geographic boundaries.
Methods: We conducted two independent but similar online global surveys to capture patient and HCP perspectives on the impact that COVID-19 has had, and the future impact it will have on HAE medical care.
Results: Both patients and HCPs globally reported that the pandemic has limited the availability of HAE medical care, and they expect the restrictions to continue far beyond the pandemic. In addition, the results of our study suggested that telehealth use has increased across the globe but has been more successfully implemented in high-income countries.
Conclusion: Patients and HCPs expect that HAE-related care will be negatively impacted by the pandemic for many years. Disparities in medical care and technologic infrastructure may exacerbate these challenges in non-high-income countries. Supportive tools and global infrastructure should be established to provide aid to non-high-income countries throughout the pandemic and several years after.

Entities:  

Mesh:

Year:  2022        PMID: 34983717      PMCID: PMC8749253          DOI: 10.2500/aap.2022.43.210099

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  24 in total

1.  Socioeconomic inequalities in health in 22 European countries.

Authors:  Johan P Mackenbach; Irina Stirbu; Albert-Jan R Roskam; Maartje M Schaap; Gwenn Menvielle; Mall Leinsalu; Anton E Kunst
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

2.  Hereditary angioedema: Epidemiology and burden of disease.

Authors:  William R Lumry; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2020-11-01       Impact factor: 2.587

3.  Effect of COVID-19 on hereditary angioedema activity and quality of life.

Authors:  Ozge Can Bostan; Gulseren Tuncay; Ebru Damadoglu; Gul Karakaya; Ali Fuat Kalyoncu
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

Review 4.  Hereditary Angioedema: The Economics of Treatment of an Orphan Disease.

Authors:  William Raymond Lumry
Journal:  Front Med (Lausanne)       Date:  2018-02-16

5.  A distributional regression approach to income-related inequality of health in Australia.

Authors:  Roselinde Kessels; Anne Hoornweg; Thi Kim Thanh Bui; Guido Erreygers
Journal:  Int J Equity Health       Date:  2020-06-22

6.  Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries.

Authors:  Irene A Kretchy; Michelle Asiedu-Danso; James-Paul Kretchy
Journal:  Res Social Adm Pharm       Date:  2020-04-15

7.  COVID-19: The impact of social distancing policies, cross-country analysis.

Authors:  Gonzalo Castex; Evgenia Dechter; Miguel Lorca
Journal:  Econ Disaster Clim Chang       Date:  2020-10-15

8.  Impact of anxiety, stress and depression related to COVID-19 pandemic on the course of hereditary angioedema with C1-inhibitor deficiency.

Authors:  Deniz Eyice Karabacak; Semra Demir; Osman Ozan Yeğit; Ali Can; Kadriye Terzioğlu; Derya Ünal; Müge Olgaç; Raif Coşkun; Bahauddin Çolakoğlu; Suna Büyüköztürk; Aslı Gelincik
Journal:  Allergy       Date:  2021-05-15       Impact factor: 14.710

9.  The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries.

Authors:  Patrick G T Walker; Charles Whittaker; Oliver J Watson; Marc Baguelin; Peter Winskill; Arran Hamlet; Bimandra A Djafaara; Zulma Cucunubá; Daniela Olivera Mesa; Will Green; Hayley Thompson; Shevanthi Nayagam; Kylie E C Ainslie; Sangeeta Bhatia; Samir Bhatt; Adhiratha Boonyasiri; Olivia Boyd; Nicholas F Brazeau; Lorenzo Cattarino; Gina Cuomo-Dannenburg; Amy Dighe; Christl A Donnelly; Ilaria Dorigatti; Sabine L van Elsland; Rich FitzJohn; Han Fu; Katy A M Gaythorpe; Lily Geidelberg; Nicholas Grassly; David Haw; Sarah Hayes; Wes Hinsley; Natsuko Imai; David Jorgensen; Edward Knock; Daniel Laydon; Swapnil Mishra; Gemma Nedjati-Gilani; Lucy C Okell; H Juliette Unwin; Robert Verity; Michaela Vollmer; Caroline E Walters; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; David G Lalloo; Neil M Ferguson; Azra C Ghani
Journal:  Science       Date:  2020-06-12       Impact factor: 47.728

View more
  3 in total

1.  Evaluation and management of adverse reactions to the COVID-2019 vaccines.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

2.  Long-COVID and loss of smell: A post-COVID olfactory dysfunction that continues to challenge the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-03-01       Impact factor: 2.587

3.  Eosinophilic esophagitis: from discovery to effective treatment.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-05-01       Impact factor: 2.873

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.